EQUIP

Densitas® Selects CancerIQ to Power Lifetime Risk, Patient Adherence as Part of its Industry Leading Mammography Quality AI Platform

Retrieved on: 
Sunday, November 26, 2023

"Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas.

Key Points: 
  • "Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas.
  • Densitas offers a robust AI-driven mammography quality assurance platform that comprises intelliMammo® and intelliMaven™.
  • This integrated platform provides mammography facilities and clinical care teams with a comprehensive and scalable solution that boosts operational efficiency, improves mammography quality, and increases clinical confidence.
  • Importantly, it ensures compliance with the FDA's Mammography Quality Standards Act (MQSA) EQUIP and the American College of Radiology's standards.

Volpara Health ushers in new era of breast imaging at RSNA 2023

Retrieved on: 
Wednesday, November 22, 2023

CHICAGO, Nov. 22, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will showcase its latest software advancements at the Annual Radiological Society of North America (RSNA) meeting, November 26-29, 2023 (South Hall, Booth #2780).

Key Points: 
  • This comprehensive cancer risk assessment software capitalizes on the opportunity of mammography and wellness appointments to personalize care.
  • The Volpara AI-powered solutions on display at RSNA excel at automating manual, time-consuming and subjective tasks to help providers and patients thrive in this new era."
  • The Elizabeth Wende Breast Center will report on the outcomes of five years of high-risk screening with supplemental MRI and genetic testing.
  • The scientific poster shows that using Volpara Risk Pathways and Volpara density assessment software can lead to better outcomes through implementing risk assessment in a large community-based program.

Volpara highlights cancer risk assessment, breast density assessment and mammography quality software at SBI 2023

Retrieved on: 
Wednesday, May 3, 2023

LYNNWOOD, Wash., May 3, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection of cancer, is attending the 2023 Society of Breast Imaging annual symposium, May 4-7 in Maryland. The company will be showcasing how breast care professionals can use its software to quantify cancer risk and provide personalized care planning as well as help improve efficiency, accuracy and quality of the whole mammography process.

Key Points: 
  • The company will be showcasing how breast care professionals can use its software to quantify cancer risk and provide personalized care planning as well as help improve efficiency, accuracy and quality of the whole mammography process.
  • Using Volpara Risk Pathways™ healthcare providers can use their existing EHR such as Epic® or mammography system workflows like Volpara's Patient Hub™ to assess a patient's a risk of developing multiple forms of cancer.
  • This broad cancer risk assessment capability adds value to the entire health system by capitalizing on the opportunity of mammography appointments to personalize and coordinate care without disrupting workflow.
  • To learn more about cancer risk assessment, breast density assessment and education, or image quality, visit Volpara at SBI booth #307.

GitLab Foundation Makes its First Grant to Help Job Seekers and Employers Make Sense of Postsecondary Credentials

Retrieved on: 
Monday, April 17, 2023

BOSTON, April 17, 2023 /PRNewswire/ -- Today, the GitLab Foundation—formed by GitLab, Inc to improve people's lifetime earnings globally through access to opportunities —has announced its first major grant of $2.9 million to national nonprofit Jobs for the Future (JFF) in collaboration with the Burning Glass Institute.

Key Points: 
  • "Access to education and training helps workers build new skills and advance in their professional lives, driving income growth and economic mobility," said Ellie Bertani, CEO of the GitLab Foundation.
  • Our collaboration with JFF and the Burning Glass Institute aims to increase transparency across credential programs in the US and help learners and employers make more informed decisions."
  • In the absence of a validated means for candidates to signal their skills, many employers have clung to degree requirements.
  • That's starting to change: Burning Glass Institute research indicates that the prevalence of degree requirements has dropped 14% since 2017.

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Retrieved on: 
Tuesday, December 6, 2022

We are very pleased to partner itolizumab with Ono, a leading Japanese pharmaceutical company dedicated to fighting disease and pain, said Bruce Steel, Chief Executive Officer at Equillium.

Key Points: 
  • We are very pleased to partner itolizumab with Ono, a leading Japanese pharmaceutical company dedicated to fighting disease and pain, said Bruce Steel, Chief Executive Officer at Equillium.
  • We are very pleased to be partnering with Equillium to develop a novel medicine for patients with difficult-to-treat immuno-inflammatory disorders.
  • Management will host a conference call to discuss the option and asset purchase agreement with Ono Pharmaceutical Co., Ltd. for analysts and institutional investors, at 8:30 a.m.
  • Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas.

Desert Imaging Deploys densitas® intelliMammo™ A.I. Solutions for Breast Screening Services

Retrieved on: 
Tuesday, November 29, 2022

solutions for digital mammography and breast screening announced that Desert Imaging has implemented the densitas IntelliMammo platform across their health system.

Key Points: 
  • solutions for digital mammography and breast screening announced that Desert Imaging has implemented the densitas IntelliMammo platform across their health system.
  • IntelliMammoprovides Desert Imaging with on-demand actionable information and streamlined workflows to establish efficient, effective, and sustainable quality assurance and compliance processes.
  • Densitas is a global leader in artificial intelligence solutions for breast cancer screening, focused on quality, safety, efficiency, and precision breast health.
  • Headquartered in El Paso, Texas, Desert Imaging Services, LP, is a privately-owned diagnostic imaging company that combines state-of-the-art technology with compassionate, quality care.

Lokithor J401 New Release Tops Amazon Jump Starter Best Sellers List

Retrieved on: 
Saturday, October 29, 2022

1 in Amazon's Best Sellers and Hot New Releases within 15 minutes of its launch on October 22.

Key Points: 
  • 1 in Amazon's Best Sellers and Hot New Releases within 15 minutes of its launch on October 22.
  • The Best Sellers list and the Hot New Release list is Amazon's competitive ranking system for sales.
  • Lokithor New Release Ranked Top 1 Amazon Best Seller in the U.S.
    Jump Starter products have always been one of the most popular products in the auto parts category in the U.S. market.
  • Compared with the traditional Jump Starter clips, it has a better grip, is more labor-saving, and is also stable.

Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

Retrieved on: 
Thursday, May 12, 2022

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.
  • Published data in the Journal of Clinical Investigation confirming the role of T cells activated by the CD6-ALCAM pathway in the development of lupus nephritis.
  • Acquired in-process research and development (IPR&D) expenses for the first quarter of 2022 were $23.0 million resulting from the accounting for the Bioniz acquisition.
  • Cash used in operations for the first quarter of 2022 was $12.1 million compared to $10.2 million in the fourth quarter of 2021.

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

Retrieved on: 
Thursday, May 12, 2022

For more information and access to the abstract, visit the EHA Open Access Library .

Key Points: 
  • For more information and access to the abstract, visit the EHA Open Access Library .
  • Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

Retrieved on: 
Monday, May 9, 2022

Collectively, these presentations suggest that the CD6-ALCAM pathway is an attractive target for autoimmune and inflammatory diseases and that itolizumab may be ideally suited to target this pathway.

Key Points: 
  • Collectively, these presentations suggest that the CD6-ALCAM pathway is an attractive target for autoimmune and inflammatory diseases and that itolizumab may be ideally suited to target this pathway.
  • Key Highlights, Summary and Conclusions from Presentation:
    First study to directly characterize the role of CD6 in the development and activity of T regulatory cells.
  • T regulatory cells derived from CD6 low cells had greater co-expression of FOXP3 and HELIOS (~2-fold) vs. T regulatory cells derived from isotype-treated CD6 high cells.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.